• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Medtronic to Separate Diabetes Business into New Standalone Company

by Jasmine Pennic 05/21/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Medtronic today announced its strategic decision to separate its Diabetes business into a new, independent, publicly traded company (“New Diabetes Company”). 

– The move aims to create a more focused Medtronic, with a simplified portfolio concentrated on high-margin growth markets, while simultaneously establishing a scaled, independent leader in the diabetes sector.

– The separation is expected to be completed within 18 months through a series of capital markets transactions, with a preferred path involving an initial public offering (IPO) followed by a subsequent split-off. This transaction is anticipated to unlock value for Medtronic and its shareholders.

A More Focused Medtronic, A Dedicated Diabetes Leader

This strategic shift will allow Medtronic to intensify its focus on innovation-driven growth and category leadership in other attractive MedTech markets. 

“Active portfolio management is an important lever to delivering on our ongoing growth and success, and this decision shifts the Medtronic portfolio to have intense focus on our highest margin growth drivers where we have our strongest core competencies,” said Geoff Martha, chairman and CEO of Medtronic. Medtronic is building momentum with growth drivers such as pulsed field ablation, renal denervation, implantable tibial neuromodulation, and soft tissue robotics. Post-separation, Medtronic expects to drive durable, mid-single digit or higher organic revenue growth and accelerate earnings leverage.

At the same time, the New Diabetes Company will emerge as a leading, scaled, direct-to-consumer diabetes business, uniquely positioned as the only company to commercialize a complete ecosystem for intensive insulin management. This independence is expected to enable more focused investment in the New Diabetes Company’s pipeline, manufacturing scale, and automation, positioning it for success in Automated Insulin Delivery and Smart MDI, while driving margin expansion over time.

Que Dallara Appointed CEO

Que Dallara, current EVP and president of Medtronic Diabetes, will become CEO of the New Diabetes Company. The Diabetes business currently comprises over 8,000 employees worldwide, with a global commercial footprint and dedicated innovation, manufacturing, clinical, and quality systems.

Transaction Details and Timeline

The separation will create an independent, publicly traded company, with Medtronic’s preferred path being an IPO of the New Diabetes Company followed by a split-off transaction. This approach is expected to appropriately capitalize the New Diabetes Company and provide the ability to retire Medtronic shares. The separation is generally anticipated to be tax-free to Medtronic shareholders for U.S. federal income tax purposes. The New Diabetes Company will inherit the Diabetes business employees, product portfolio, pipeline, intellectual property, strategic partnerships, and global manufacturing facilities.

Medtronic is targeting completion of this planned separation within 18 months, subject to customary conditions, including favorable market conditions, consultations with works councils and other employee representative bodies, final approval from the Medtronic Board of Directors, receipt of a favorable tax opinion, and applicable regulatory approvals.

Financial Benefits of the Separation

The Diabetes business represented 8% of Medtronic’s revenue and 4% of its segment operating profit in fiscal year 2025. Upon completion, the separation is expected to improve Medtronic’s adjusted gross margin by approximately 50 basis points and its adjusted operating margins by approximately 100 basis points, while being immediately accretive to adjusted EPS. The transaction is also expected to provide the ability to retire Medtronic shares outstanding without reducing cash, resulting in EPS accretion and a reduction in dividend liability for Medtronic, enabling increased investment in growth-accretive areas. Medtronic anticipates its dividend per share will remain unchanged post-transaction, with no change to its dividend policy.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Diabetes Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |